High consequence infectious diseases (HCID)
Guidance and information about high consequence infectious diseases and their management in England.
Definition of HCID
In the UK, a high consequence infectious disease (HCID) is defined according to the following criteria:
- acute infectious disease
- typically has a high case-fatality rate
- may not have effective prophylaxis or treatment
- often difficult to recognise and detect rapidly
- ability to spread in the community and within healthcare settings
- requires an enhanced individual, population and system response to ensure it is managed effectively, efficiently and safely
Classification of HCIDs
HCIDs are further divided into contact and airborne groups:
-
contact HCIDs are usually spread by direct contact with an infected patient or infected fluids, tissues and other materials, or by indirect contact with contaminated materials and fomites
-
airborne HCIDs are spread by respiratory droplets or aerosol transmission, in addition to contact routes of transmission
List of high consequence infectious diseases
A list of HCIDs has been agreed by the UK 4 nations public health agencies, with advisory committee input as required:
| Contact HCIDs | Airborne HCIDs |
|---|---|
| Argentine haemorrhagic fever (Junin virus) | Andes virus infection (hantavirus) |
| Bolivian haemorrhagic fever (Machupo virus) | Avian influenza A H7N9 and H5N1 |
| Crimean Congo haemorrhagic fever (CCHF) | Avian influenza A H5N6 and H7N7* |
| Ebola virus disease (EVD) | Middle East respiratory syndrome (MERS) |
| Lassa fever | Mpox (monkeypox) (Clade I only)** |
| Lujo virus disease | Nipah virus infection |
| Marburg virus disease (MVD) | Pneumonic plague (Yersinia pestis) |
| Severe fever with thrombocytopaenia syndrome (SFTS) | Severe acute respiratory syndrome (SARS)*** |
*Human-to-human transmission has not been described to date for avian influenza A(H5N6). Human to human transmission has been described for avian influenza A(H5N1), although this was not apparent until more than 30 human cases had been reported. Both A(H5N6) and A(H5N1) often cause severe illness and fatalities. Therefore, A(H5N6) has been included in the airborne HCID list despite not meeting all of the HCID criteria.
**Based on the new WHO nomenclature, the mpox virus is comprised of 2 clades: Clade I (formerly Congo Basin (Central African) Clade) and Clade II (formerly West African Clade). Clade II consists of the subclades Clade IIa and Clade IIb, with the latter subclade referring mainly to the group of variants circulating in the 2022 global outbreak. See HCID status of mpox for further details on status classification.
***No cases reported since 2004, but SARS remains a notifiable disease under the International Health Regulations (2005), hence its inclusion here.
The list of HCIDs will be kept under review and updated by the UK 4 nations public health agencies, with advisory committee input as required, if new HCIDs emerge that are of relevance to the UK.
Status of COVID-19
As of 19 March 2020, COVID-19 is no longer considered to be an HCID in the UK. There are many diseases which can cause serious illness which are not classified as HCIDs.
The 4 nations public health HCID group made an interim recommendation in January 2020 to classify COVID-19 as an HCID. This was based on consideration of the UK HCID criteria about the virus and the disease with information available during the early stages of the outbreak. Now that more is known about COVID-19, the public health bodies in the UK have reviewed the most up to date information about COVID-19 against the UK HCID criteria. They have determined that several features have now changed; in particular, more information is available about mortality rates (low overall), and there is now greater clinical awareness and a specific and sensitive laboratory test, the availability of which continues to increase.
The ACDP is also of the opinion that COVID-19 should no longer be classified as an HCID.
The World Health Organization (WHO) continues to consider COVID-19 as a Public Health Emergency of International Concern (PHEIC), therefore the need to have a national, coordinated response remains and this is being met by the government’s COVID-19 response.
Cases of COVID-19 are no longer managed by HCID treatment centres only. Healthcare workers managing possible and confirmed cases should follow the National infection prevention and control manual for England (or the equivalent devolved administration infection prevention and control manuals), which includes instructions about different personal protective equipment (PPE) ensembles that are appropriate for different clinical scenarios.
HCIDs in the UK
HCIDs, including viral haemorrhagic fevers (VHFs), are rare in the UK. When cases do occur, they tend to be sporadic and are typically associated with recent travel to an area where the infection is known to be endemic or where an outbreak is occurring. None of the HCIDs listed above are endemic in the UK, and the known animal reservoirs are not found in the UK.
As of July 2022, the UK has experience of managing confirmed cases of Lassa fever, EVD, CCHF, MERS and mpox. The vast majority of these patients acquired their infections overseas, but secondary transmission of MERS and mpox have occurred in the UK.
In May 2022, cases of mpox (Clade IIb, at that time classified as an HCID) without a history of travel overseas were reported in the UK. More information is available in the epidemiological overview of this outbreak.
Avian influenza A(H5N1) has caused outbreaks in wild birds and captive birds in the UK in 2021 and 2022. In January 2022, the UK Health Security Agency (UKHSA) reported the first human case of avian influenza A(H5N1) in the UK. Animal-to-human transmission of avian influenza is very rare and the risk to human health is kept under frequent review. The epidemiology and genomics of A(H5N1) virus and human health risk is actively monitored by UKHSA, in collaboration with international partners.
HCID risks by country
For health professionals wishing to determine the HCID risk in any particular country, an A to Z list of countries and their respective HCID risk is available.
See HCID country risks.
Monthly summaries of global HCID events
UKHSA’s epidemic intelligence activities monitor global HCID events. These are published in a monthly summary.
Infection prevention and control in healthcare settings
Specific infection prevention and control (IPC) measures are required for suspected and confirmed HCID cases, in all healthcare settings (specialist and non-specialist).
IPC guidance appropriate for suspected and confirmed cases of Lassa fever, EVD, CCHF, MVD, Lujo virus disease, Argentinian haemorrhagic fever, Bolivian haemorrhagic fever and SFTS, is available in the ACDP guidance.
IPC guidance for MERS, avian influenza, Nipah virus infection, mpox and pneumonic plague, can be found in the relevant UKHSA guidance listed below.
Links to relevant UKHSA guidance for healthcare professionals
Specialist advice for healthcare professionals
The Imported Fever Service (IFS) provides 24-hour, 7-days a week telephone access to expert clinical and microbiological advice. Hospital doctors across the UK can contact the IFS after discussion with the local microbiology, virology or infectious disease consultant.
Hospital management of confirmed HCID cases
Once an HCID has been confirmed by appropriate laboratory testing, cases in England should be transferred rapidly to a designated HCID Treatment Centre. Occasionally, highly probable cases may be moved to an HCID Treatment Centre before laboratory results are available.
Contact HCIDs
There are 2 principal Contact HCID Treatment Centres in England:
-
the Royal Free London High Level Isolation Unit (HLIU)
-
the Newcastle Royal Victoria Infirmary HLIU.
Further support for managing confirmed contact HCID cases is provided by the Royal Liverpool Hospital and the Royal Hallamshire Hospital, Sheffield.
Airborne HCIDs
There are 5 interim Airborne HCID Treatment Centres in England. Adult and paediatric services are provided by 7 NHS Trusts:
- Guy’s and St Thomas’ NHS Foundation Trust (adult and paediatric services)
- Royal Free London NHS Foundation Trust, with a paediatric service provided by Imperial College Healthcare NHS Foundation Trust
- Royal Liverpool and Broadgreen University Hospitals NHS Trust, with a paediatric service provided by Alder Hey Children’s NHS Foundation Trust
- Newcastle upon Tyne Hospitals NHS Foundation Trust (adult and paediatric services)
- Sheffield Teaching Hospitals NHS Foundation Trust (adult service only)
Case transfer arrangements
Hospital clinicians seeking to transfer confirmed HCID cases, or discuss the transfer of highly probable HCID cases, should contact the NHS England EPRR Duty Officer. It is expected that each case will have been discussed with the Imported Fever Service before discussing transfer.
Travel health advice for HCIDs
The National Travel Health Network and Centre (NaTHNaC) provides travel health information about a number of HCIDs, for healthcare professionals and travellers. Advice can be accessed via the Travel Health Pro website.
Updates to this page
Last updated 25 January 2023 + show all updates
-
Updated in line with the HCID derogation of Clade II mpox (monkeypox). Added information about the first human case of avian influenza A(H5N1) reported in the UK.
-
Updated to reflect changes to the HCID status of monkeypox.
-
Updated to reflect the change in monkeypox clade nomenclature.
-
Updated to reflect clade of monkeypox virus involved in community transmission in the UK being declassified as an HCID.
-
Added link to Andes hantavirus guidance.
-
Added link to page on severe fever with thrombocytopaenia syndrome (SFTS).
-
Updated 'Status of COVID-19' section.
-
Added Sheffield Teaching Hospitals NHS Foundation Trust to the list of airborne HCID treatment centres in England.
-
Added explanation of the removal of COVID-19 from the list of HCIDs in the UK.
-
Added Wuhan novel coronavirus
-
Amended the definitions for HCID.
-
Added explanation for inclusion of avian influenza H5N6 as an HCID.
-
Added link to information on HCID risks by country.
-
First published.